Latest news with #ThermoFisherScientificInc.
Yahoo
29-05-2025
- Health
- Yahoo
Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs
Researchers can obtain deeper insights from cells with more colors and faster time to results with minimal sample volume WALTHAM, Mass., May 29, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today launched the spectral-enabled Invitrogen™ Attune™ Xenith™ Flow Cytometer, allowing immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples. By leveraging Thermo Fisher's legacy core acoustic focusing technology, this new solution offers improved time to results for scientists researching cellular behaviors and mechanisms and discovering targeted therapies. It enables both spectral unmixing and conventional flow cytometry, allowing researchers to tackle a broader range of applications with greater flexibility and sensitivity. As the field of flow cytometry grows and research needs become more complex, scientists require access to even more data from cells which can help provide insights into how diseases, including cancer, manifest and progress in the body. Traditional cytometers frequently face issues with complex data analysis, non-intuitive interfaces and frequent clogs, which can slow down the research process and cause waste of often irreplaceable tissue samples. The Attune Xenith Flow Cytometer addresses these common problems with its user-friendly software and a multitude of innovative features: High-Speed Acoustic Technology: Accelerates sample analysis, significantly reducing processing times while maintaining exceptional sensitivity. Clog-Resistant Design: Reduces stoppages and sample waste, allowing labs to operate more reliably with minimal sample volume. Higher Parametric Analysis: Equipped with six lasers and 51 fluorescent detectors, enabling detailed and accurate insights from each sample. Longer Uptime: Designed for extended operation without needing fluid changes, maximizing lab productivity. Built-in cameras, automated maintenance and remote diagnostics help ensure ease of use for researchers of all experience levels. "We're thrilled to have the opportunity to provide immunologists and other researchers with a solution that not only allows the rapid analysis of parameters, but one that will also speed up the discovery and translation of critical research findings," said Trisha Dowling, vice president of flow and imaging technologies at Thermo Fisher Scientific. "The Invitrogen Attune Xenith Flow Cytometer can handle a higher volume of samples quickly and efficiently, allowing scientists to analyze cells with exceptional precision." "The Attune Xenith flow cytometer is a robust and powerful instrument that allows our users to quickly set up assays in conventional or spectral mode with flexibility and the well-known reliability and high-speed acoustics of the Attune product line," shared Dr. Juan J. Garcia Vallejo, MD, PhD, MBA, Associate Professor for Molecular Cell Biology & Immunology, and Scientific Director of the Microscopy and Cytometry Core Facility of the Amsterdam UMC, who uses the instrument in his lab. The Attune Xenith Flow Cytometer is the latest advancement in Thermo Fisher Scientific's extensive portfolio of flow cytometry solutions, including the Attune CytPix and NxT instruments. Its introduction reinforces the company's longstanding commitment to advancing scientific knowledge by offering innovative tools that enhance lab efficiency, data accuracy and overall research capabilities. To learn more about the Attune Xenith, please visit our website and register for the webinar on June 18. *For research use only. Not for use in diagnostic procedures. About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit © 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. View source version on Contacts Media Contact Information:Name : Dana MaxwellPhone: (760) 859-8539E-mail: Name: Tiffany Keenan, GreenoughPhone: (603) 913-3893E-mail: tkeenan@ Sign in to access your portfolio
Business Wire
29-05-2025
- Science
- Business Wire
Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today launched the spectral-enabled Invitrogen™ Attune™ Xenith™ Flow Cytometer, allowing immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples. By leveraging Thermo Fisher's legacy core acoustic focusing technology, this new solution offers improved time to results for scientists researching cellular behaviors and mechanisms and discovering targeted therapies. It enables both spectral unmixing and conventional flow cytometry, allowing researchers to tackle a broader range of applications with greater flexibility and sensitivity. As the field of flow cytometry grows and research needs become more complex, scientists require access to even more data from cells which can help provide insights into how diseases, including cancer, manifest and progress in the body. Traditional cytometers frequently face issues with complex data analysis, non-intuitive interfaces and frequent clogs, which can slow down the research process and cause waste of often irreplaceable tissue samples. The Attune Xenith Flow Cytometer addresses these common problems with its user-friendly software and a multitude of innovative features: High-Speed Acoustic Technology: Accelerates sample analysis, significantly reducing processing times while maintaining exceptional sensitivity. Clog-Resistant Design: Reduces stoppages and sample waste, allowing labs to operate more reliably with minimal sample volume. Higher Parametric Analysis: Equipped with six lasers and 51 fluorescent detectors, enabling detailed and accurate insights from each sample. Longer Uptime: Designed for extended operation without needing fluid changes, maximizing lab productivity. Built-in cameras, automated maintenance and remote diagnostics help ensure ease of use for researchers of all experience levels. 'We're thrilled to have the opportunity to provide immunologists and other researchers with a solution that not only allows the rapid analysis of parameters, but one that will also speed up the discovery and translation of critical research findings,' said Trisha Dowling, vice president of flow and imaging technologies at Thermo Fisher Scientific. 'The Invitrogen Attune Xenith Flow Cytometer can handle a higher volume of samples quickly and efficiently, allowing scientists to analyze cells with exceptional precision.' 'The Attune Xenith flow cytometer is a robust and powerful instrument that allows our users to quickly set up assays in conventional or spectral mode with flexibility and the well-known reliability and high-speed acoustics of the Attune product line,' shared Dr. Juan J. Garcia Vallejo, MD, PhD, MBA, Associate Professor for Molecular Cell Biology & Immunology, and Scientific Director of the Microscopy and Cytometry Core Facility of the Amsterdam UMC, who uses the instrument in his lab. The Attune Xenith Flow Cytometer is the latest advancement in Thermo Fisher Scientific's extensive portfolio of flow cytometry solutions, including the Attune CytPix and NxT instruments. Its introduction reinforces the company's longstanding commitment to advancing scientific knowledge by offering innovative tools that enhance lab efficiency, data accuracy and overall research capabilities. To learn more about the Attune Xenith, please visit our website and register for the webinar on June 18. *For research use only. Not for use in diagnostic procedures. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit © 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.
Yahoo
18-04-2025
- Business
- Yahoo
Ozone Meter Market Size, Share, Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030
Growth is fueled by rising air quality concerns and strict environmental regulations. Ozone meters, essential for tracking atmospheric ozone levels, are increasingly used in manufacturing, automotive, and agriculture sectors. Technological advancements like IoT integration and real-time monitoring enhance demand. However, the high cost of these devices remains a challenge for widespread adoption, particularly in developing regions. Key players include Aeroqual Limited, Thermo Fisher Scientific Inc., and HORIBA, Ltd. Ozone Meter Market Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Ozone Meter Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to offering. Global Ozone Meter Market, valued at USD 1.42 billion in 2024, is projected to reach USD 2.06 billion by 2030, registering a robust CAGR of 6.2% through 2030. This growth is fueled by increasing emphasis on air quality monitoring and environmental protection as ozone pollution raises health and environmental concerns. Industries like manufacturing, automotive, agriculture, and research institutes are adopting ozone meters to comply with stringent environmental regulations. The rise in industrialization and urbanization in developing economies has spiked the demand for these devices to mitigate air pollution impacts. Continuous advancements in ozone measurement technology enhance market growth. Modern ozone meters provide improved accuracy, real-time monitoring, and portability, thanks to developments in digital sensors and IoT integration. These technological improvements make ozone meters more versatile and cost-effective for industries such as manufacturing and agriculture. Approximately 40-45% of market demand stems from environmental monitoring applications, assessing urban and rural ozone pollution impacts on climate change. However, the high cost of advanced ozone measurement devices poses a challenge. Acquisition and maintenance costs can restrict adoption, particularly in developing regions or among smaller enterprises. The need for periodic calibration and maintenance adds financial strain, potentially hindering market growth. Addressing this, manufacturers are encouraged to explore affordable solutions to increase ozone meter adoption in cost-sensitive locations. A prominent market trend is the integration of ozone meters with IoT and cloud-based platforms, enabling real-time, remote monitoring. This shift improves air quality management efficiency, offering predictive maintenance and reducing device downtime. The trend, aligned with rising demand for smart, connected devices, enhances data sharing with stakeholders, boosting regulatory compliance and decision-making. Supported by funding like the EU's Horizon 2020 program, market expansion is anticipated in manufacturing, transportation, and environmental monitoring sectors. Key Attributes: Report Attribute Details No. of Pages 181 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.42 Billion Forecasted Market Value (USD) by 2030 $2.06 Billion Compound Annual Growth Rate 6.2% Regions Covered Global Companies Featured Aeroqual Limited Thermo Fisher Scientific Inc. HORIBA, Ltd. Teledyne Technologies Incorporated Ludlum Measurements, Inc. Lutron Electronic Enterprise Co., LTD. Micromeritics Instrument Corporation MSA Worldwide, LLC For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Ozone Meter Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Associated Press
26-02-2025
- Health
- Associated Press
Thermo Fisher Scientific Launches CorEvitas Clinical Registry and Biorepository in Systemic Lupus Erythematosus
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the CorEvitas Systemic Lupus Erythematosus (SLE) Registry. The multi-center, prospective registry leverages the CorEvitas rheumatology physician network and addresses a critical unmet need for collecting robust, objective real-world data about this chronic and devastating autoimmune disease, in which the immune system attacks healthy tissue and can cause damage to patients' skin, joints, blood and internal organs, including the kidneys, heart, brain and lungs. The registry will leverage clinician and patient insights to address key questions about the safety and effectiveness of available and future treatments for SLE, the most common type of lupus. Patients diagnosed with SLE experience symptoms ranging from mild to severe or even life-threatening, and commonly include extreme fatigue, joint and muscle pain, headache, fever, alopecia and sensitivity to light. Approximately 90% of SLE patients are women. The exact cause is unknown, however it is believed that environmental, genetic and hormonal factors can contribute. SLE can affect many parts of the body, and symptoms often manifest differently across patients and fluctuate over time, making diagnosis and treatment difficult. A small number of biologics have recently been approved to treat SLE, with an exciting array of targeted and cellular therapies in development. The registry collects clinical data longitudinally from both enrolled patients and their treating rheumatologists across multiple health outcome domains, including drug utilization, quality of life, disease activity and severity, medical comorbidities, diagnostic tests and adverse events. With a large, clinically rich data set and a supporting team of experts in epidemiology, biostatistics and drug safety at their fingertips, researchers can derive unique insights to address a range of critical questions related to the treatment of SLE. 'This independent, multi-drug registry and linked biorepository fill a critical gap for our clients and the broader research community, particularly as newer therapies and treatment paradigms are prescribed,' said Jeffrey Greenberg, M.D., chief medical officer, CorEvitas, part of the PPD™ clinical research business of Thermo Fisher Scientific. 'High-quality, real-world data can drive much-needed insights on novel treatments and provide hope for patients suffering from this chronic illness.' This is the 13 th independent CorEvitas registry, building on a robust rheumatology network and foundational efforts to address unmet research needs in rheumatological conditions. As the U.S. has the second-highest incidence of SLE globally, the registry will consist of SLE patients in North America under the care of a rheumatologist. It is complemented by a CorEvitas SLE biorepository, which collects blood specimens linked to clinical data from enrolled registry patients to support a range of additional use cases, including drug discovery and development, as well as the development of biomarkers to predict disease progression and drug response. This registry was launched with the scientific guidance of advisors Anca Askanase, M.D., MPH, professor of medicine, Columbia University Medical Center, and George Tsokos, M.D., professor of medicine, Harvard Medical School. CorEvitas services include proprietary autoimmune and inflammatory disease registries containing structured, regulatory-grade patient clinical data spanning more than 500 investigator sites and over 100,000 patients followed longitudinally. The CorEvitas independent registry model has been accepted by regulators for long-term post-authorization safety studies across a variety of disease indications. To learn more about this study and the newly launched registry, request information at [email protected]. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit SOURCE: Thermo Fisher Copyright Business Wire 2025. PUB: 02/26/2025 08:15 AM/DISC: 02/26/2025 08:15 AM
Yahoo
13-02-2025
- Business
- Yahoo
Growth Opportunities in the $4.1 Bn Emission Monitoring Systems Market, 2025-2029 & 2034
Thermo Fisher Scientific Inc., Teledyne Technologies Inc., Sick AG, Parker-Hannifin Corporation, and Siemens AG Lead the Competition Emission Monitoring System Market Dublin, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The "Emission Monitoring System Market Report 2025" has been added to emission monitoring system market size has grown strongly in recent years. It will grow from $3.73 billion in 2024 to $4.1 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to regulatory compliance, public awareness, industrial growth, cost reduction. The emission monitoring system market size is expected to see strong growth in the next few years. It will grow to $5.96 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to global climate initiatives, renewable energy expansion, government incentives. Major trends in the forecast period include advancements in sensor technology, data analytics and ai integration, remote monitoring and cloud-based solutions, focus on green solutions, global collaboration for standardization, decentralized energy growing demand from the oil and gas, as well as power generation industries, is expected to drive the growth of the emission monitoring systems market. For example, in June 2024, the Energy Information Administration, a US-based government agency, projected that U.S. crude oil production would rise by 2% from its 2023 level, reaching an average of 13.2 million barrels per day (b/d) in 2024. Additionally, a further 4% increase is expected in 2025, bringing production to 13.7 million b/d. Therefore, the rising consumption of oil and natural gas is likely to boost the demand for emission monitoring systems in the increasing use of coal-fired power plants for energy generation is expected to drive the growth of the emission monitoring systems market. For example, reports published in July 2023 by the Department for Energy Security & Net Zero, a UK-based organization, indicated that the demand for coal by electricity generators slightly increased from 127 thousand metric tons in Q2 2023 to 135 thousand metric tons in Q2 2024. Consequently, the growing reliance on coal-fired power plants for energy generation is likely to boost the demand for emission monitoring systems in the advancements are significantly influencing the emission monitoring system market. Many companies are leveraging new technologies to offer improved and enhanced products to their customers. For example, in August 2024, Honeywell International Inc., a US-based technology firm, introduced the Advanced Emissions Monitoring System specifically designed for offshore oil and gas platforms. This innovative system is part of Honeywell's broader Emissions Management Suite, which aims to provide a comprehensive solution for measuring, monitoring, reporting, and reducing emissions in the energy sector. The system is designed to deliver end-to-end solutions that enable accurate detection and real-time reporting of fugitive emissions. This capability is essential for offshore operations, where emissions can have a significant impact on regulatory compliance and environmental companies in the emission monitoring system market are exploring the XE10 Continuous Emissions Monitoring System (CEMS) to gain a competitive edge and enhance their product offerings. For instance, in August 2024, the Council of Scientific and Industrial Research-National Physical Laboratory (CSIR-NPL), a research organization based in India, launched a comprehensive certification for Continuous Emission Monitoring Systems throughout the country. This certification aims to provide real-time measurements of air and water pollution and includes components for sampling, conditioning, and analysis to ensure accurate and continuous monitoring of emissions from industrial sources. The introduction of this certification process is regarded as a significant advancement in improving the quality of emission data in India. This initiative seeks to enhance the reliability and effectiveness of pollution monitoring across various industries, addressing long-standing concerns regarding data accuracy and compliance with environmental America was the largest region in the emission monitoring system market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emission monitoring system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the emission monitoring system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain. Report Scope Markets Covered:1) By System Type: Continuous Emission Monitoring System (CEMS); Predictive Emission Monitoring System (PEMS)2) By Component Outlook: Hardware; Software; Service3) By Industry: Marine and Shipping; Mining; Metals; Pharmaceuticals; Pulp and Paper; Building Materials; Chemicals, Petrochemicals, Refineries and Fertilizers; Oil and Gas; Power GenerationSubsegments:1) By Continuous Emission Monitoring System (CEMS): Gas Monitoring Systems; Particulate Monitoring Systems; Data Acquisition and Management Systems; Calibration and Validation Systems2) By Predictive Emission Monitoring System (PEMS): Software Solutions for Emission Forecasting; Data Integration Tools; Algorithm Development Services; Reporting and Compliance SolutionsKey Companies Profiled: Thermo Fisher Scientific Inc.; Teledyne Technologies Inc.; Sick AG; Parker-Hannifin Corporation; Siemens AGTime Series: Five years historic and ten years Ratios of market size and growth to related markets, GDP proportions, expenditure per Segmentation: Country and regional historic and forecast data, market share of competitors, market Attributes Report Attribute Details No. of Pages 200 Forecast Period 2025-2029 Estimated Market Value (USD) in 2025 $4.1 Billion Forecasted Market Value (USD) by 2029 $5.96 Billion Compound Annual Growth Rate 9.8% Regions Covered Global Companies Featured in this Emission Monitoring System Market Report Thermo Fisher Scientific Inc. Teledyne Technologies Inc. Sick AG Parker-Hannifin Corporation Siemens AG General Electric Company Emerson Electric Co AMETEK Inc. ABB Ltd. CMC Solutions LLC Environmental SA Pvt. Ltd. Opsis AB Ecotech Technologies Pvt. Ltd. Intertek Group plc Analytical Technology Inc. Bacharach Inc. Beijing SDL Technology Company Limited California Analytical Instruments Inc. Codel International Ltd. The Durag Group E Instruments International LLC ECO PHYSICS AG ENVEA Societe Anonyme Fuji Electric Co. Ltd. Gasmet Technologies Oy Horiba Ltd. KANE International Ltd. KIMO Instruments Land Instruments International Ltd. M&C TechGroup Germany GmbH Testo SE & Co. KGaA Yokogawa Electric Corporation For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Emission Monitoring System Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
